Effects of mammary cancer and chemotherapy on neuroimmunological markers and memory function in a preclinical mouse model

Colleen Netherby-Winslow,Bryan Thompson,Louis Lotta,Mark Gallagher,Paige Van Haute,Rachel Yang,Devin Hott,Hamza Hasan,Katherine Bachmann,Javier Bautista,Scott Gerber,Deborah A Cory-Slechta,Michelle Janelsins

DOI: https://doi.org/10.1016/j.bbih.2023.100699

2023-11-07

Abstract:Treatment modalities for breast cancer, including cyclophosphamide chemotherapy, have been associated with the development of cognitive decline (CRCD), which is characterized by impairments in memory, concentration, attention, and executive functions. We and others have identified a link between inflammation and decreased cognitive performance in patients with breast cancer receiving chemotherapy. In order to better understand the inflammation-associated molecular changes within the brain related to tumor alone or in combination with chemotherapy, we orthotopically implanted mouse mammary tumors (E0771) into female C57BL/6 mice and administered clinically relevant doses of cyclophosphamide and doxorubicin intravenously at weekly intervals for four weeks. We measured serum cytokines and markers of neuroinflammation at 48 h and up to one month post-treatment and tested memory using a reward-based delayed spatial alternation paradigm. We found that breast tumors and chemotherapy altered systemic inflammation and neuroinflammation. We further found that the presence of tumor and chemotherapy led to a decline in memory over time at the longest delay, when memory was the most taxed, compared to shorter delay times. These findings in a clinically relevant mouse model shed light on possible biomarkers for CRCD and add to the growing evidence that anti-inflammatory strategies have the potential to mitigate cancer- or treatment-related side effects.